A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871
This study is recruiting at 29 US sites in 19 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HER2 Mutation-Related Tumors
- HER2
- HER2-positive Breast Cancer
- HER2 + Breast Cancer
- Brain Metastases From Solid Tumors
- Brain Metastases From HER2 and Breast Cancer
- CNS Metastases
- HER2-Positive Solid Tumors
- NSCLC (Non-small Cell Lung Cancer)
- HER2-positive Bladder Cancer
- HER2-positive Colorectal Cancer
- HER2 + Gastric Cancer
- HER2-positive Gastroesophageal Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Iambic Therapeutics, Inc
- Last updated on ClinicalTrials.gov
- September 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UCSD Moores Cancer Center · La Jolla, CA
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
Colorado · 1
- University of Colorado Cancer Center · Aurora, CO
Florida · 2
- University of Miami · Miami, FL
- Comprehensive Hematology Oncology · St. Petersburg, FL
Illinois · 1
- University of Chicago · Chicago, IL
Massachusetts · 2
- Dana Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Michigan · 3
- University of Michigan · Ann Arbor, MI
- Henry Ford Cancer Institute · Detroit, MI
- START - Midwest Cancer Research Center · Grand Rapids, MI
Missouri · 2
- Saint Luke's Cancer Institute · Kansas City, MO
- Washington University School of Medicine · St Louis, MO
New Hampshire · 1
- Dartmouth Hitchcock Medical · Lebanon, NH
New Jersey · 1
- Rutgers Cancer Institute · New Brunswick, NJ
New York · 1
- Icahn School of Medicine at Mount Sinai · New York, NY
North Carolina · 1
- Duke Cancer Institute · Durham, NC
Ohio · 2
- Cleveland Clinic · Cleveland, OH
- University Hospital Cleveland Medical Center · Cleveland, OH
Oklahoma · 1
- OU Health Stephenson Cancer Center · Oklahoma City, OK
Oregon · 1
- Providence Cancer Institute · Portland, OR
Tennessee · 2
- SCRI Oncology Partners · Nashville, TN
- Vanderbilt Ingram Cancer Center · Nashville, TN
Texas · 3
- NEXT Oncology - Austin · Austin, TX
- Mary Crowley Cancer Research · Dallas, TX
- MD Anderson Cancer Center - University of Texas · Houston, TX
Utah · 1
- START Mountain Region · West Valley City, UT
Virginia · 1
- NEXT Oncology - Virginia Cancer Specialists · Fairfax, VA
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.